Treatment of recurrent hepatitis C following liver transplantation

详细信息    查看全文

• 作者：Douglas Meyer MD
  Kirti Shetty MD (1)
  
• 刊名：Current Hepatitis Reports
• 出版年：2007
• 出版时间：May 2007
• 年：2007
• 卷：6
• 期：2
• 页码：54-59
• 全文大小：214KB
• 参考文献：1. Organ Procurement and Transplantation Network (OPTN) database. Available at http://www.optn.org. Accessed December 30, 2006.
  2. Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting the future healthcare burden from hepatitis C in the United States. / Liver Transpl 2003, 9:331鈥?38. CrossRef
  3. Berenguer M, Prieto M, Rayon JM, et al.: Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. / Hepatology 2000, 32:852鈥?58. CrossRef
  4. Berenguer M, Ferrell L, Watson J, et al.: HCV-related fibrosis progression following liver transplantation: increase in recent years. / J Hepatology 2000, 32:673鈥?84. CrossRef
  5. Forman LM, Lewis JD, Berlin JA, et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation. / Gastroenterology 2002, 122:889鈥?96. CrossRef
  6. Garcia-Retortillo M, Forns X, Feliu, et al.: Hepatitis C virus kinetics during and immediately after liver transplantation. / Hepatology 2002, 35:680鈥?87. CrossRef
  7. Schluger LK, Sheiner PA, Thung SN, et al.: Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. / Hepatology 1996, 23:971鈥?76. CrossRef
  8. Charlton M, Seaberg E, Wiesner R, et al.: Predictors of patient and graft survival following liver transplantation for hepatitis C. / Hepatology 1998, 28:823鈥?30. CrossRef
  9. Thuluvath P, Yoo H: Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. / Liver Transpl 2004, 10:1263鈥?268. CrossRef
  10. Garcia-Retortillo M, Forns X, Llovet J, et al.: Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. / Hepatology 2004, 40:699鈥?07. CrossRef
  11. Russo MW, Galanko J, Beavers K, et al.: Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. / Liver Transpl 2004, 10:340鈥?46. CrossRef
  12. Shiffman M, Stravitz RT, Contos MJ, et al.: Histologic recurrence of chronic hepatitis C in patients after living donor and deceased donor liver transplantation. / Liver Transpl 2004, 10:1248鈥?255. CrossRef
  13. Terrault NA, Shiffman ML, Lok ASF, et al.: Outcomes in hepatitis C virus-infected recipients of living donor vs deceased donor liver transplantation. / Liver Transpl 2007, 13:122鈥?29. CrossRef
  14. Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. / Liver Transpl 2002, 8:362鈥?69. CrossRef
  15. Charlton M, Seaberg E: Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. / Liver Transpl Surg 1999, 5(4 suppl 1):S107鈥揝114.
  16. Zervos XA, Weppler D, Fragulidis GP, et al.: Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. / Transplantation 1998, 65:1044鈥?046. CrossRef
  17. Wiesner RH, Shorr JS, Steffen BJ, et al.: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. / Liver Transpl 2005, 11:750鈥?59. CrossRef
  18. Rosen HR, Shackleton CR, Higa L, et al.: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. / Am J Gastroenterol 1997, 92:1453鈥?457.
  19. Crippin JS, McCashland TM, Terrault NA, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus infected patients awaiting liver transplantation. / Liver Transpl 2002, 8:350鈥?55. CrossRef
  20. Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. / Hepatology 2005, 42:255鈥?62. CrossRef
  21. Shergill A, Khalili M, Bollinger K, et al.: Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. / Am J Transplant 2005, 5:118鈥?24. CrossRef
  22. Mazzaferro V, Tagger A, Schiavo M, et al.: Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. / Transplant Proc 2001, 33:1355鈥?357. CrossRef
  23. Chalasani N, Manzarbietia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. / Hepatology 2005, 41:289鈥?98. CrossRef
  24. Sugawara Y, Makuuchi M, Matsui Y, et al.: Preemptive therapy for hepatitis C virus after living donor liver transplantation. / Transplantation 2004, 78:1308鈥?311. CrossRef
  25. Feray C, Gigou M, Samuel D, et al.: Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. / Ann Intern Med 1998, 128:810鈥?16.
  26. Krawczynski K, Alter M, Tankersley D, et al.: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. / J Infect Dis 1996, 173:822鈥?28.
  27. Willems B, Marotta P, Greig PD, et al.: Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation [abstract]. / J Hepatol 2002, 36:S96A. CrossRef
  28. Davis GL, Nelson DR, Terrault NA, et al.: A randomized open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. / Liver Transpl 2005, 11:941鈥?49. CrossRef
  29. Schiano TD, Charlton M, Younossi Z, et al.: Monoclonal antibody HCV-AbXTL 68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. / Liver Transpl 2006, 12:1381鈥?389. CrossRef
  30. Mukherjee S: Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation / Transpl Proc 2005, 37:4403鈥?405. CrossRef
  31. Oton E, Barcena R, Garcia-Garzon S, et al.: Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. / Transpl Proc 2005, 37:3963鈥?964. CrossRef
  32. Biselli M, Andreone P, Gramenzi A, et al.: Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. / Dig Liver Dis 2006, 38:27鈥?2. CrossRef
  33. Dumortier J, Scoazec JY, Chevallier P, et al.: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. / J Hepatol 2004, 40:669鈥?94. CrossRef
  34. Mukherjee S, Rogge J, Weaver L, et al.: Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. / Transpl Proc 2003, 35:3042鈥?044. CrossRef
  35. Berenguer M, Palau A, Fernandez A, et al.: Efficacy, predictors of response and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. / Liver Transpl 2006, 12:1067鈥?076. CrossRef
  36. Stravitz RT, Shiffman M, Sanyal A, et al.: Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. / Liver Transpl 2004, 10:850鈥?58. CrossRef
  37. Saab S, Kalmaz D, Gajjar N, et al.: Outcomes of acute rejection after interferon therapy in liver transplant recipients. / Liver Transpl 2004, 10:859鈥?67. CrossRef
  38. Kugelmas M, Osgood MJ, Trotter JF, et al.: Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. / Liver Transpl 2003, 9:1159鈥?165. CrossRef
  39. Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al.: Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. / Liver Transpl 2005, 11:1567鈥?573. CrossRef
  40. Neff G, O鈥橞rien C, Nery J, et al.: Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. / Liver Transpl 2004, 10:1497鈥?503. CrossRef
  
• 作者单位：Douglas Meyer MD
  Kirti Shetty MD (1)
  
  1. Georgetown University Hospital, 2 Main, 3800 Reservoir Road, NW, 20007, Washington, DC, USA
  

文摘

Patients with chronic hepatitis C infection who are viremic at the time of liver transplantation will have universal recurrence of the virus in the allograft. Long-term survival after transplantation in patients with chronic hepatitis C is diminished as compared with patients who undergo liver transplantation for other indications. The progression of HCV-related fibrosis and the development of cirrhosis appear to be accelerated in the presence of immunosuppression, compared with an immune-competent population. The primary aim of hepatitis C treatment in patients with recurrent hepatitis C infection in the allograft remains eradication of the virus to prevent the progression of liver disease. However, decisions regarding the timing, duration, and optimization of the treatment regimen must be tailored to the individual.